|
1
|
Fujioka T and Obara W: Committee for
Establishment of the Clinical Practice Guideline for the Management
of Renal Cell Carcinoma and the Japanese Urological Association:
Evidence-based clinical practice guideline for renal cell
carcinoma: The Japanese Urological Association 2011 update. Int J
Urol. 19:496–503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kovacs G, Akhtar M, Beckwith BJ, Bugert P,
Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros
LJ, et al: The Heidelberg classification of renal cell tumours. J
Pathol. 183:131–133. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shenoy N and Pagliaro L: Sequential
pathogenesis of metastatic VHL mutant clear cell renal cell
carcinoma: Putting it together with a translational perspective.
Ann Oncol. 27:1685–1695. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Razafinjatovo C, Bihr S, Mischo A, Vogl U,
Schmidinger M, Moch H and Schraml P: Characterization of VHL
missense mutations in sporadic clear cell renal cell carcinoma:
Hotspots, affected binding domains, functional impact on pVHL and
therapeutic relevance. BMC Cancer. 16:6382016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arjumand W and Sultana S: Role of VHL gene
mutation in human renal cell carcinoma. Tumour Biol. 33:9–16. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adams KF, Leitzmann MF, Albanes D, Kipnis
V, Moore SC, Schatzkin A and Chow WH: Body size and renal cell
cancer incidence in a large US cohort study. Am J Epidemiol.
168:268–277. 2008.PubMed/NCBI
|
|
7
|
Luo J, Margolis KL, Adami HO, Lopez AM,
Lessin L and Ye W: Women's Health Initiative Investigators: Body
size, weight cycling, and risk of renal cell carcinoma among
postmenopausal women: The Women's Health Initiative (United
States). Am J Epidemiol. 166:752–759. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lipworth L, Tarone RE, Lund L and
McLaughlin JK: Epidemiologic characteristics and risk factors for
renal cell cancer. Clin Epidemiol. 1:33–43. 2009.PubMed/NCBI
|
|
9
|
Calle EE and Kaaks R: Overweight, obesity
and cancer: Epidemiological evidence and proposed mechanisms. Nat
Rev Cancer. 4:579–591. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fischer-Posovszky P, Wabitsch M and
Hochberg Z: Endocrinology of adipose tissue - an update. Horm Metab
Res. 39:314–321. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raucci R, Rusolo F, Sharma A, Colonna G,
Castello G and Costantini S: Functional and structural features of
adipokine family. Cytokine. 61:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balistreri CR, Caruso C and Candore G: The
role of adipose tissue and adipokines in obesity-related
inflammatory diseases. Mediators Inflamm. 2010:8020782010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Riondino S, Roselli M, Palmirotta R,
Della-Morte D, Ferroni P and Guadagni F: Obesity and colorectal
cancer: Role of adipokines in tumor initiation and progression.
World J Gastroenterol. 20:5177–5190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ye J, Jia J, Dong S, Zhang C, Yu S, Li L,
Mao C, Wang D, Chen J and Yuan G: Circulating adiponectin levels
and the risk of breast cancer: A meta-analysis. Eur J Cancer Prev.
23:158–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song CH, Liao J, Deng ZH, Zhang JY, Xue H,
Li YM, Liang C, Han M, Zhang K and Yan GT: Is leptin a predictive
factor in patients with lung cancer? Clin Biochem. 47:230–232.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tun HW, Marlow LA, von Roemeling CA,
Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ and
Copland JA: Pathway signature and cellular differentiation in clear
cell renal cell carcinoma. PLoS One. 5:e106962010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lenburg ME, Liou LS, Gerry NP, Frampton
GM, Cohen HT and Christman MF: Previously unidentified changes in
renal cell carcinoma gene expression identified by parametric
analysis of microarray data. BMC Cancer. 3:312003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gati A, Kouidhi S, Marrakchi R, El Gaaied
A, Kourda N, Derouiche A, Chebil M, Caignard A and Perier A:
Obesity and renal cancer: Role of adipokines in the tumor-immune
system conflict. OncoImmunology. 3:e278102014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gulen ST, Karadag F, Karul AB, Kilicarslan
N, Ceylan E, Kuman NK and Cildag O: Adipokines and systemic
inflammation in weight-losing lung cancer patients. Lung.
190:327–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ntikoudi E, Kiagia M, Boura Pand and
Syrigos KN: Hormones of adipose tissue and their biologic role in
lung cancer. Cancer Treat Rev. 40:22–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gonullu G, Kahraman H, Bedir A, Bektas A
and Yücel I: Association between adiponectin, resistin, insulin
resistance, and colorectal tumors. Int J Colorectal Dis.
25:205–212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Spyridopoulos TN, Petridou ET, Dessypris
N, Terzidis A, Skalkidou A, Deliveliotis C and Chrousos GP: Obesity
and Cancer Oncology Group: Inverse association of leptin levels
with renal cell carcinoma: Results from a case-control study.
Hormones (Athens). 8:39–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liao LM, Weinstein SJ, Pollak M, Li Z,
Virtamo J, Albanes D, Chow WH and Purdue MP: Prediagnostic
circulating adipokine concentrations and risk of renal cell
carcinoma in male smokers. Carcinogenesis. 34:109–112. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shimizu H and Mori M: Role of leptin and
its receptor in the regulation of appetite and body fat. Nihon
Rinsho. 59:421–426. 2001.(In Japanese). PubMed/NCBI
|
|
26
|
Yuan HJ, Sun KW and Yu K: Leptin promotes
the proliferation and migration of human breast cancer through the
extracellular-signal regulated kinase pathway. Mol Med Rep.
9:350–354. 2014.PubMed/NCBI
|
|
27
|
Zhou W, Guo S and Gonzalez-Perez RR:
Leptin pro-angiogenic signature in breast cancer is linked to IL-1
signalling. Br J Cancer. 104:128–137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen C, Chang YC, Lan MS and Breslin M:
Leptin stimulates ovarian cancer cell growth and inhibits apoptosis
by increasing cyclin D1 and Mcl-1 expression via the activation of
the MEK/ERK1/2 and PI3K/Akt signaling pathways. Int J Oncol.
42:1113–1119. 2013.PubMed/NCBI
|
|
29
|
Mohammadzadeh G, Ghaffari MA, Bafandeh A
and Hosseini SM: Association of serum soluble leptin receptor and
leptin levels with breast cancer. J Res Med Sci. 19:433–438.
2014.PubMed/NCBI
|
|
30
|
Horiguchi A, Sumitomo M, Asakuma J, Asano
T, Zheng R, Asano T, Nanus DM and Hayakawa M: Increased serum
leptin levels and over expression of leptin receptors are
associated with the invasion and progression of renal cell
carcinoma. J Urol. 176:1631–1635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liao LM, Schwartz K, Pollak M, Graubard
BI, Li Z, Ruterbusch J, Rothman N, Davis F, Wacholder S, Colt J, et
al: Serum leptin and adiponectin levels and risk of renal cell
carcinoma. Obesity (Silver Spring). 21:1478–1485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stastny J, Bienertova-Vasku J and Vasku A:
Visfatin and its role in obesity development. Diabetes Metab Syndr.
6:120–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bi TQ and Che XM: Nampt/PBEF/visfatin and
cancer. Cancer Biol Ther. 10:119–125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Li X, Liu KR, Zhang JN, Liu Y and
Zhu Y: Visfatin derived from ascites promotes ovarian cancer cell
migration through Rho/ROCK signaling-mediated actin polymerization.
Eur J Cancer Prev. 24:231–239. 2014. View Article : Google Scholar
|
|
35
|
Li XY, Tang SH, Zhou XC, Ye YH, Xu XQ and
Li RZ: Preoperative serum visfatin levels and prognosis of breast
cancer among Chinese women. Peptides. 51:86–90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakajima TE, Yamada Y, Hamano T, Furuta K,
Matsuda T, Fujita S, Kato K, Hamaguchi T and Shimada Y:
Adipocytokines as new promising markers of colorectal tumors:
Adiponectin for colorectal adenoma, and resistin and visfatin for
colorectal cancer. Cancer Sci. 101:1286–1291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lu GW, Wang QJ, Xia MM and Qian J:
Elevated plasma visfatin levels correlate with poor prognosis of
gastric cancer patients. Peptides. 58:60–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sorli SC, Le Gonidec S, Knibiehler B and
Audigier Y: Apelin is a potent activator of tumour neoangiogenesis.
Oncogene. 26:7692–7699. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang L, Su T, Lv D, Xie F, Liu W, Cao J,
Sheikh IA, Qin X, Li L and Chen L: ERK1/2 mediates lung
adenocarcinoma cell proliferation and autophagy induced by
apelin-13. Acta Biochim Biophys Sin (Shanghai). 46:100–111. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Heo K, Kim YH, Sung HJ, Li HY, Yoo CW, Kim
JY, Park JY, Lee UL, Nam BH, Kim EO, et al: Hypoxia-induced
up-regulation of apelin is associated with a poor prognosis in oral
squamous cell carcinoma patients. Oral Oncol. 48:500–506. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Diakowska D, Markocka-Mączka K,
Szelachowski P and Grabowski K: Serum levels of resistin,
adiponectin, and apelin in gastroesophageal cancer patients.
Disease Markers. 2014:6196492014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Curat CA, Wegner V, Sengenès C, Miranville
A, Tonus C, Busse R and Bouloumié A: Macrophages in human visceral
adipose tissue: Increased accumulation in obesity and a source of
resistin and visfatin. Diabetologia. 49:744–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hivert MF, Sullivan LM, Fox CS, Nathan DM,
D'Agostino RB Sr, Wilson PW and Meigs JB: Associations of
adiponectin, resistin, and tumor necrosis factor-alpha with insulin
resistance. J Clin Endocrinol Metab. 93:3165–3172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dalamaga M, Sotiropoulos G, Karmaniolas K,
Pelekanos N, Papadavid E and Lekka A: Serum resistin: A biomarker
of breast cancer in postmenopausal women? Association with
clinicopathological characteristics, tumor markers, inflammatory
and metabolic parameters. Clin Biochem. 46:584–590. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yildiz Y, Ozaksit G, Unlu B Serdar, Ozgu
E, Energin H, Kaba M and Ugur M: Serum adiponectin level and
clinical, metabolic, and hormonal markers in patients with
polycystic ovary syndrome. Int J Fertil Steril. 7:331–336.
2014.PubMed/NCBI
|
|
46
|
Hebbard L and Ranscht B: Multifaceted
roles of adiponectin in cancer. Best Pract Res Clin Endocrinol
Metab. 28:59–69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Spyridopoulos TN, Petridou ET, Skalkidou
A, Dessypris N, Chrousos GP and Mantzoros CS: Obesity and Cancer
Oncology Group: Low adiponectin levels are associated with renal
cell carcinoma: A case-control study. Int J Cancer. 120:1573–1578.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gulcelik MA, Colakoglu K, Dincer H, Dogan
L, Yenidogan E and Gulcelik NE: Associations between adiponectin
and two different cancers: Breast and colon. Asian Pac J Cancer
Prev. 13:395–398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dalamaga M, Diakopoulos KN and Mantzoros
CS: The role of adiponectin in cancer: A review of current
evidence. Endocr Rev. 33:547–594. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Izadi V, Farabad E and Azadbakht L: Serum
adiponectin level and different kinds of cancer: A review of recent
evidence. ISRN Oncol. 2012:9827692012.PubMed/NCBI
|
